BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker

Reuters03-18

** Shares of biotech firm Arvinas ARVN.O rise 2% to $12.22 premarket

** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial

** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days

** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP

** Adds no serious side effects were reported and all adverse events were mild

** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback

** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620423080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620423080","market":"us","top_or_hot":-1,"title":"BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker</title></head><body><p>** Shares of biotech firm Arvinas <span>ARVN.O</span> rise 2% to $12.22 premarket</p><p>** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial</p><p>** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days</p><p>** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP</p><p>** Adds no serious side effects were reported and all adverse events were mild</p><p>** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback</p><p>** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker</title></head><body><p>** Shares of biotech firm Arvinas <span>ARVN.O</span> rise 2% to $12.22 premarket</p><p>** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial</p><p>** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days</p><p>** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP</p><p>** Adds no serious side effects were reported and all adverse events were mild</p><p>** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback</p><p>** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL4N4060WP:1","article_id":"2620423080","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620423080","pubTimestamp":1773832700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker** Shares of biotech firm Arvinas ARVN.O rise 2% to $12.22 premarket** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP** Adds no serious side effects were reported and all adverse events were mild** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC","BK4007":"制药"},"translate_title":"早期试验显示药物可降低帕金森病的关键标志物后，BUZZ-Arvinas上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":0.9},"content_text":"BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker** Shares of biotech firm Arvinas ARVN.O rise 2% to $12.22 premarket** Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial** Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days** Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP** Adds no serious side effects were reported and all adverse events were mild** Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback** ARVN shares up 1.26% YTD vs. a ~38% decline in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620423080","isCrawlerRequest":true}